After a little more than a year of working with Sanofi, Santa Clarita’s MannKind announced Tuesday it is terminating its partnership with the Paris-based marketing and distribution firm.
MannKind said it is ending its license and collaboration agreement with Sanofi for the development and commercialization of Afrezza, MannKind’s diabetes treatment device that delivers fast-acting insulin through inhaled powder.
The new treatment device, more than a decade in the making and at a cost of more than $1 billion to the biomedical company, eliminates the need for injection by needle and makes it so sufferers do not have to time their injections precisely relative to a meal.
After the Food and Drug Administration’s approval of Afrezza in late June 2014, the agreement between MannKind and Sanofi was announced in August of that year.
Sanofi has been responsible for global commercial, regulatory and development activities. The drug has been manufactured at MannKind’s Connecticut plant.
Under the agreement with Sanofi, MannKind received an initial upfront cash infusion of $150 million for the licensing agreement. The two firms also had a global profit- and loss-sharing arrangement.
But Afrezza sales never attained levels the company had hoped for, causing the company’s stock to drop steadily.
Former CEO Hakan Edstrom stepped down in late November after 11 months on the job, and founder Alfred Mann stepped in temporarily to fill the role until Duane M. DeSisto was appointed in December to take over, effective on Tuesday.
The partnership change was DeSisto’s first public move.
Sales have been an uphill climb since first going to market, and MannKind’s stock has steadily dropped from a 52-week high of $7.88 per share to less than a dollar Tuesday morning when the announcement was made.
MannKind said the parties will enter discussions to design a smooth and orderly transition over the next three to six months.
Termination of the license will be effective no later than July 4, 2016.
